Access to expensive cancer drugs limited in Korea

Published: 2013-06-12 06:57:00

Updated: 2013-06-12 06:57:00

Korea has restricted access to very expensive cancer therapies in terms of fairness index and transparency, when compared to advanced countries, according to a report presented at the 2013 American Society of Clinical Oncology (ASCO) annual meeting.

When comparing access to high-cost cancer d...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK